Good agreement seen for stool characterization by novel smartphone app compared with expert opinion of two gastroenterologists
TUESDAY, May 31, 2022 (HealthDay News) — A novel smartphone application can accurately determine Bristol Stool Scale (BSS) and other visual stool characteristics, according to a study recently published in the American Journal of Gastroenterology and presented at the 2022 Digestive Disease Week, held from May 21 to 24 in San Diego.
Mark Pimentel, M.D., from Cedars-Sinai in Los Angeles, and colleagues evaluated the accuracy of a novel smartphone application that uses trained artificial intelligence to assess stool characteristics.
The researchers found that in the validation phase, there was good agreement between two experts and AI characterizations for BSS, stool consistency, edge fuzziness, fragmentation, and volume. Compared with self-reports from study participants with diarrhea-predominant irritable bowel syndrome, AI outperformed for categorizing daily average BSS scores as constipation, normal, or diarrhea. Agreement between AI and self-reported BSS scores in the implementation phase was moderate. For diarrhea severity scores, AI stool characterization was found to correlate better than participant reports.
“The artificial intelligence tool removes the subjective description that can be part of a patient’s description of their bowel specimens,” a coauthor said in a statement. “In addition to improving a physician’s ability to assess their patients’ digestive health, this app could be advantageous for clinical trials by reducing the variability of stool outcome measures.”
One author is an employee and board member of Dieta Health.
Abstract/Full Text (subscription or payment may be required)
People With ADHD Experience 50 Percent More GI Symptoms
Smartwatches Significantly Overestimate How Many Calories Are Burned
Bowel Urgency in Ulcerative Colitis Linked to Disease-Related Disability
Remote Patient-Reported Outcome Monitoring Empowers Patients With Cancer
Most Specialty Oral Anticancer Meds for Blood Cancers Are Initially Rejected by Insurers
Personalized Support Boosts Families" Genetic Testing for Hereditary Cancers
Pre-Prostate Biopsy MRI Use Increased From 2017 to 2026
Cancer Survivors Have Lower Levels of Physical Activity